Last reviewed · How we verify
mometasone furoate nasal spray
mometasone furoate nasal spray is a Small molecule drug developed by Organon and Co. It is currently FDA-approved. Also known as: NASONEX®, MK-0887, SCH 032088, nasonex.
Mometasone furoate nasal spray, marketed by Organon and Co, holds a significant position in the nasal corticosteroid segment. A key strength is the protection provided by its composition patent, which is set to expire in 2028. The primary risk is the potential increase in competition following the patent expiry, which could impact market share and revenue.
At a glance
| Generic name | mometasone furoate nasal spray |
|---|---|
| Also known as | NASONEX®, MK-0887, SCH 032088, nasonex, Nasonex |
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study (PHASE2)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps (PHASE2)
- A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps (PHASE2)
- Research on Underlying Causes of Long-term Use of Nasal Decongestants and the Structured Withdrawal of the Decongestant (PHASE4)
- A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps (PHASE2)
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mometasone furoate nasal spray CI brief — competitive landscape report
- mometasone furoate nasal spray updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about mometasone furoate nasal spray
What is mometasone furoate nasal spray?
Who makes mometasone furoate nasal spray?
Is mometasone furoate nasal spray also known as anything else?
What development phase is mometasone furoate nasal spray in?
Related
- Manufacturer: Organon and Co — full pipeline
- Also known as: NASONEX®, MK-0887, SCH 032088, nasonex, Nasonex
- Compare: mometasone furoate nasal spray vs similar drugs
- Pricing: mometasone furoate nasal spray cost, discount & access